AtaiBeckley Employee Directory

AtaiBeckley corporate office is located in 250 W 34th St, New York, New York, 10119, United States and has 51-200 employees.

Employees by Department

Departments

Number of employees

C-Suite

8

Operations

8

Engineering & Technical

7

Medical & Health

6

Finance

4

Legal

4

Marketing

1

Key Employees of AtaiBeckley

AtaiBeckley Global Presence

globalPresence illustration
North America11-50
Europe11-50

Index of contact profiles from AtaiBeckley

Hundreds of professionals searching for AtaiBeckley have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
123

Former Employees at AtaiBeckley

Explore people who held key positions, contributed to AtaiBeckley's success, and advanced their careers.

People from Similar Companies in the Business Services Industry Located in New York, United States

Frequently Asked Questions Regarding AtaiBeckley Employees

How many employees does AtaiBeckley have?
AtaiBeckley has 51-200 employees
Who are AtaiBeckley key employees?
Some of AtaiBeckley key employees are Gerd Kochendoerfer, Frank Wiegand, Ryan Barrett
Where is AtaiBeckley located?
AtaiBeckley’s headquarters are located at 250 W 34th St, New York, New York, 10119, United States
How do I contact AtaiBeckley?
AtaiBeckley Contact Info: Phone number: (332) 282-0507 Website: www.ataibeckley.com
What does AtaiBeckley do?

AtaiBeckley is a clinical-stage biopharmaceutical company headquartered in New York and Amsterdam, focused on developing rapid-acting and convenient mental health treatments to transform patient outcomes. Formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited completed in November 2025, the company brings togethe... r world-class science and clinical expertise with a pipeline of investigational psychedelic-based neuroplastogens designed to address urgent unmet needs in mental health. AtaiBeckley's lead program is BPL-003, a novel mebufotenin benzoate nasal spray designed to produce rapid and durable antidepressive effects from a single dose for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA and is Phase 3-ready. The company's diversified pipeline also includes VLS-01, a DMT buccal film for treatment-resistant depression currently in Phase 2 clinical trials, EMP-01, an oral R-MDMA being evaluated for social anxiety disorder, and a portfolio of novel 5-HT2A receptor agonists, including non-hallucinogenic neuroplastogens, in earlier stages of development. Led by CEO and Co-Founder Dr. Srinivas Rao and an experienced executive team with deep expertise in neuroscience, psychiatry, and drug development, AtaiBeckley aims to create commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. The company is publicly traded on NASDAQ under the ticker symbol ATAI.Read More

Is AtaiBeckley a public company?
Yes, AtaiBeckley is a public company and is traded under the symbol ATAI
See more information about AtaiBeckley Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.